KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Fulgent Genetics (FLGT) Income from Continuing Operations (2016 - 2025)

Fulgent Genetics' Income from Continuing Operations history spans 11 years, with the latest figure at 32485000.0 for Q4 2025.

  • For Q4 2025, Income from Continuing Operations fell 20.0% year-over-year to 32485000.0; the TTM value through Dec 2025 reached 5496000.0, down 284.12%, while the annual FY2025 figure was 8266000.0, 376.18% down from the prior year.
  • Income from Continuing Operations for Q4 2025 was 32485000.0 at Fulgent Genetics, up from 6826000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 200691000.0 in Q1 2021 and bottomed at 213482000.0 in Q4 2022.
  • The 5-year median for Income from Continuing Operations is 7933500.0 (2024), against an average of 13865950.0.
  • The largest annual shift saw Income from Continuing Operations skyrocketed 11856.94% in 2021 before it crashed 1100.74% in 2023.
  • A 5-year view of Income from Continuing Operations shows it stood at 103677000.0 in 2021, then tumbled by 305.91% to 213482000.0 in 2022, then surged by 37.07% to 134334000.0 in 2023, then soared by 130.23% to 40604000.0 in 2024, then decreased by 20.0% to 32485000.0 in 2025.
  • Per Business Quant, the three most recent readings for FLGT's Income from Continuing Operations are 32485000.0 (Q4 2025), 6826000.0 (Q3 2025), and 19256000.0 (Q2 2025).